Foundayo side effects: Common symptoms, serious risks and when to get help

What are the most common Foundayo side effects?

The UK Patient Information Leaflet (PIL) uses standard frequency categories rather than giving a percentage for every effect. 'Very common' means more than 1 in 10 people may be affected; 'common' means up to 1 in 10; and 'uncommon' means up to 1 in 100. [1]

Frequency in the UK PIL	Side effects listed
Very common	Nausea, constipation, diarrhoea, vomiting, indigestion (dyspepsia), abdominal pain
Common	Dizziness, headache, fast pulse, low blood pressure, abdominal bloating, burping, reflux or heartburn, gas, gallstones, hair loss, fatigue, increased pancreatic enzymes in the blood
Uncommon	Unusual sense of taste, unpleasant or abnormal feeling when touched (dysesthesia)

Low blood sugar is treated separately in the PIL because its frequency changes substantially according to the other diabetes medicines being used. [1]

The MHRA also identifies nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain as the most common effects seen with orforglipron. [2]

How quickly Foundayo side effects start, and how long they last

There is no single day on which Foundayo side effects start or stop. The UK PIL says nausea, diarrhoea and vomiting are most common when first starting orforglipron and decrease over time in most patients. In the 72-week ATTAIN-1 obesity trial, gastrointestinal adverse events also occurred mainly during dose escalation and were mostly mild to moderate. [1][3]

That supports a useful general pattern: digestive symptoms are more likely to be noticed around starting treatment and dose increases. It does not mean every symptom will settle, or that persistent symptoms should simply be waited out.

If nausea, vomiting, diarrhoea, constipation or abdominal symptoms are persisting, worsening, making it difficult to eat or drink, or affecting whether you can take treatment as prescribed, contact your prescriber. Do not change the dose or stop Foundayo on your own unless a clinician tells you to do so. [1]

What you should do if you develop side effects

How you respond should depend on the symptom and its severity, not just on whether it appears in a list of known side effects.

What you notice	Why it matters	What to do
Mild nausea, diarrhoea, vomiting or other digestive symptoms that are manageable and improving	These are recognised common effects, especially around starting treatment or dose escalation	Keep taking Foundayo as prescribed. Maintain adequate fluid intake. Contact your prescriber if symptoms persist, worsen or become difficult to manage. [1]
Persistent vomiting or diarrhoea, particularly if you are struggling to maintain fluids or already have kidney problems	Dehydration can contribute to kidney problems	Contact your prescriber or seek same-day clinical advice. [1]
Severe constipation with severe abdominal pain, a swollen abdomen, vomiting, or being unable to pass wind or open your bowels	These are symptoms described in the PIL for possible bowel obstruction	Seek urgent medical advice. NHS 111 can advise if you are unsure where to be assessed. [1]
Sudden changes in vision or other unusual visual symptoms	Sudden visual changes are listed among serious effects of unknown frequency	Contact a doctor promptly. [1]
Upper abdominal pain with yellowing of the skin or eyes, pale or clay-coloured stools, or fever	These can indicate a gallbladder problem	Seek prompt clinical assessment. [1]
Severe, persistent abdominal pain, particularly if it spreads to the back	This can be a sign of acute pancreatitis	Seek urgent medical assessment. NHS guidance advises urgent GP or NHS 111 assessment for sudden severe abdominal pain; call 999 or go to A&E if severe pain spreads to the back with features such as persistent bloating, a fast heartbeat or difficulty breathing. [1][4]
Breathing difficulty, swelling of the face or throat, wheezing, pale or cold skin, or sudden marked dizziness or weakness	These can be signs of a serious allergic reaction	Call 999 for emergency help. [1][5]

Pancreatitis and gallbladder problems

Acute pancreatitis is listed in the UK PIL as an uncommon serious side effect, meaning it may affect up to 1 in 100 people. The warning symptom is severe pain in the stomach and back that does not go away. [1]

ATTAIN-1 recorded five adjudication-confirmed cases of mild pancreatitis among people receiving orforglipron and none in the placebo group. No complications were reported in those five cases. [3]

This needs proportionate interpretation. It is wrong to treat any stomach ache as pancreatitis, but it is also wrong to dismiss severe, persistent abdominal pain as an ordinary digestive side effect. If the pain is sudden or severe, seek urgent assessment. [1][4]

Gallstones are listed separately as a common side effect. The PIL also tells people with existing gallbladder problems to discuss them with their clinician, particularly where symptoms include upper abdominal pain, jaundice, pale or clay-coloured stools, or fever. [1]

Can Foundayo affect your kidneys?

The current UK information does not describe Foundayo as directly toxic to the kidneys. The important pathway it identifies is dehydration: nausea, vomiting and diarrhoea can lead to fluid loss, and dehydration can contribute to kidney problems. The PIL specifically says adequate fluid intake is particularly important for people who already have kidney problems. [1]

Kidney problems, sometimes requiring dialysis, are included among serious effects whose frequency is not yet known. The PIL again links the warning to dehydration resulting from vomiting or diarrhoea. [1]

ATTAIN-1 provides useful context without cancelling that warning. Under the trial's category for severe or serious acute renal events, no such events occurred in any of the three orforglipron groups, compared with one event in the placebo group. [3]

So the defensible answer is: kidney problems are part of the UK safety information, particularly where persistent gastrointestinal symptoms cause dehydration. That is different from saying Foundayo has been shown to cause direct kidney damage.

Can Foundayo cause liver problems or liver failure?

Current UK patient information does not list liver failure or drug-induced liver injury as a Foundayo side effect. [1]

ATTAIN-1 did monitor liver safety. Seven people in the orforglipron groups had aminotransferase levels at least 10 times the upper limit of normal, but investigators identified alternative causes in all seven. Two participants also met additional bilirubin and ALT thresholds; both cases had alternative causes and were not considered drug-induced liver injury. [3]

That does not prove liver problems can never occur. Foundayo has only recently been authorised in the UK, and post-authorisation safety evidence is still developing. It does mean that a search for 'Foundayo liver failure' should not be converted into the claim that liver failure is an established side effect when the current UK evidence does not support that conclusion.

What about eye or vision side effects?

The UK PIL asks people with diabetic retinopathy or macular oedema to discuss this before taking Foundayo. It also lists sudden changes in vision or other unusual visual symptoms among serious effects whose frequency cannot currently be estimated. [1]

That supports a specific warning about new or sudden visual changes. It does not support a broader claim that Foundayo is known to cause blindness. If you notice a sudden or unusual change in vision, contact a doctor promptly. [1]

Low blood sugar depends on your other diabetes medicines

'Foundayo causes low blood sugar' is too broad to be useful. The UK PIL shows that the risk changes according to the medicines used alongside it. [1]

Hypoglycaemia is listed as very common when orforglipron is used with insulin in specified combinations, common when used with a sulfonylurea, and uncommon when used without insulin or a sulfonylurea. [1]

Pregnancy, breastfeeding and contraception on Foundayo

Foundayo should not be used during pregnancy. If you are planning a pregnancy, the PIL says to discuss changing treatment with your doctor because orforglipron should be stopped at least three weeks in advance. Foundayo should also not be used while breastfeeding. [1]

Orforglipron may reduce the effectiveness of oral hormonal contraceptives. The UK PIL advises considering an additional barrier method, such as condoms, or switching to a non-oral contraceptive method for 30 days after starting Foundayo and for 30 days after each dose increase. [1]

If you rely on an oral contraceptive, discuss contraception with your prescriber before starting Foundayo and before dose escalation. Do not make treatment changes without clinical advice.

Does Foundayo interact with other medicines?

Yes. The UK PIL identifies medicines that can alter the amount of orforglipron in the blood, as well as medicines whose concentrations may be increased by Foundayo. [1]

Examples that may increase orforglipron concentration include clarithromycin, itraconazole, ketoconazole, ritonavir and telaprevir. Examples that may reduce it include carbamazepine, bosentan, efavirenz, rifampicin, phenytoin and St John's wort. The PIL also says Foundayo may increase concentrations of simvastatin, rosuvastatin and topotecan. [1]

This is not a complete interaction checker. Make sure the prescriber or pharmacist reviewing Foundayo has an up-to-date list of all prescription medicines, over-the-counter products and herbal remedies you use.

Foundayo side effects, surgery and anaesthesia

The UK PIL asks patients to tell their clinician if they are due to have surgery under anaesthesia. It also lists an increased chance of food or liquid entering the lungs during surgery or other procedures among serious effects of unknown frequency. [1]

The practical point is simple: tell the clinical team responsible for the procedure that you take Foundayo. The current UK PIL does not give a universal number of days for stopping Foundayo before an operation, so this should be decided by the team managing the procedure rather than by following a generic online schedule. [1]

What did ATTAIN-1 show about overall tolerability?

ATTAIN-1 studied 3,127 adults with obesity or overweight and a weight-related condition, without diabetes, for 72 weeks. The most frequent adverse events with orforglipron were gastrointestinal and were mostly mild to moderate. They occurred mainly during dose escalation. [3]

Adverse events led to treatment discontinuation in 5.3% of the 6mg group, 7.9% of the 12mg group and 10.3% of the 36mg group, compared with 2.7% with placebo. Serious adverse events occurred in 3.8% to 5.5% of the orforglipron groups and 4.9% of the placebo group. [3]

Those trial doses were investigational capsule doses. They should not be presented as the current UK Foundayo tablet strengths of 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg and 17.2mg. The marketed UK strengths use a different dose scale. [1][3]

It is also important to distinguish a 'side effect' from an 'adverse event'. In a clinical trial, an adverse event is something that happened after treatment started; it does not automatically prove the medicine caused it. That is why the 10.3% discontinuation figure should not be translated into '1 in 10 people cannot tolerate Foundayo'. It is a result from one treatment group in one controlled trial, not a personal prediction. [3]

What about anxiety, depression, dry mouth or sexual side effects?

These are all questions people search for, but they should not be turned into established side effects without evidence.

The current UK Foundayo PIL does not list anxiety, depression, dry mouth or sexual problems as known side effects. [1] That does not prove a new symptom is unrelated to treatment. New or marked changes in mood should still be discussed with a clinician, particularly if they are severe or affecting day-to-day function.

If you develop a new, persistent or worrying symptom that is not in the leaflet, do not assume it is irrelevant. Discuss it with your prescriber, particularly if it affects your ability to eat, drink, function normally or continue treatment as prescribed.

What can online Foundayo reviews tell you?

Online reviews can be useful for understanding the questions people have about a new medicine, but they cannot tell you how common a side effect is or prove that Foundayo caused a particular symptom.

This matters especially now because Foundayo was only authorised in the UK on 10 August 2026. Many online posts will therefore reflect US use, clinical-trial participation or individual experiences rather than established UK incidence data. [2]

A useful way to read an anecdote is to separate three things: what the person says they experienced, whether that symptom is recognised in the UK PIL, and whether there is a clear action you should take if it happens to you. Serious symptoms should be handled according to current UK medical guidance rather than by copying what another person did online.

Why is Foundayo under additional monitoring?

The black triangle shown on the UK Foundayo leaflet means the medicine is subject to additional monitoring so that new safety information can be identified quickly. It does not mean the MHRA has declared Foundayo unusually dangerous. [1]

The MHRA authorised orforglipron on 10 August 2026 after assessing its safety, quality and effectiveness, and says it will keep the medicine's safety and effectiveness under close review. [2]

Why can US Foundayo safety information look different?

Medicines can have different approved product information in different countries. That is why UK patients should not assume that a warning found on a US page is automatically part of the UK regulatory position.

Important: UK and US product information is not interchangeable. Treatment decisions in the UK should be based on current UK-approved information and advice from a UK prescriber.

For example, the US Foundayo label includes a contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN2. The current UK PIL does not contain that contraindication; its 'Do not take Foundayo' section lists allergy to orforglipron or the tablet ingredients. [1][6]

This difference should not be interpreted as proof that a thyroid-related risk does or does not exist. It means the current UK-approved information and advice from a UK prescriber should be the basis for UK treatment decisions.

How can you report a suspected Foundayo side effect?

If you think Foundayo may be causing a side effect, speak to a doctor, nurse or pharmacist. Suspected reactions can also be reported directly through the MHRA Yellow Card scheme. [1][2]

A Yellow Card report records a suspected association. It does not, by itself, prove that the medicine caused the event. Reporting is still useful because it helps regulators identify possible safety signals as real-world use increases.